Bionomics Ltd

NASDAQ:BNOXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.

Contact Information

Headquarters

200 Greenhill RoadTHEBARTON, SA, Australia 5063

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Alan Fisher

President, Chief Executive Officer

Spyridon Papapetropoulos

Chief Financial Officer

Timothy Cunningham

Vice President - Clinical Development

Liz Doolin

Non-Executive Director

Errol De Souza